{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:07:54Z","timestamp":1771286874158,"version":"3.50.1"},"reference-count":51,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Bezeichnung des Gleason-Score-6 (ISUP-Gradgruppe 1)-Prostatakarzinoms als \u201eKrebs\u201c ist zunehmend Gegenstand kontroverser Diskussionen. Trotz exzellenter Prognose und geringer Metastasierungsrate f\u00fchrt die Diagnose h\u00e4ufig zu emotionaler Belastung und potenzieller \u00dcbertherapie. Die Frage nach einer alternativen, weniger stigmatisierenden Benennung gewinnt daher an Relevanz.<\/jats:p>\n                  <jats:p>Diese \u00dcbersichtsarbeit analysiert die Argumente f\u00fcr und gegen eine Umbenennung des ISUP-1-Prostatakarzinoms und beleuchtet, warum die Definition von Indolenz nicht allein durch histologische Kriterien bestimmt werden kann.<\/jats:p>\n                  <jats:p>Basierend auf aktueller Literatur und Konsensuspapieren internationaler Fachgesellschaften (ISUP\/GUPS) werden pathologisch-anatomische, klinische, molekularbiologische und bildgebende Kriterien zur Definition von Tumorindolenz kritisch bewertet.<\/jats:p>\n                  <jats:p>Weder morphologische Merkmale noch molekulare Marker oder Bildgebung allein erm\u00f6glichen eine verl\u00e4ssliche Identifikation indolenter Karzinome im Biopsat. Die diagnostische Unsicherheit wird durch die Interobservervariabilit\u00e4t zus\u00e4tzlich verst\u00e4rkt. Multidisziplin\u00e4re Strategien, die klinische, radiologische, molekulare und histopathologische Parameter integrieren, erscheinen erforderlich, um indolente Tumoren sicher zu erkennen und zu klassifizieren.<\/jats:p>\n                  <jats:p>Eine blo\u00dfe Umbenennung des GG1-Prostatakarzinoms in einen benigner klingenden Begriff greift zu kurz. Vielmehr ist eine individualisierte, multidimensionale Risikostratifizierung notwendig. Die Diskussion verdeutlicht, dass die Verantwortung f\u00fcr die Definition eines indolenten Karzinoms nicht allein bei der Pathologie liegen kann.<\/jats:p>","DOI":"10.1055\/a-2728-9305","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:12:47Z","timestamp":1766103167000},"page":"88-95","source":"Crossref","is-referenced-by-count":0,"title":["Kontroverse ISUP-1-Prostatakarzinom: Ist der Karzinombegriff gerechtfertigt \u2013 klinische oder anatomische Definition?"],"prefix":"10.1055","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-5487","authenticated-orcid":false,"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Krausewitz","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ritter","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/CEJ.0000000000000594","article-title":"Progress in cancer mortality, incidence, and survival: a global overview","volume":"29","author":"C Santucci","year":"2020","journal-title":"Eur J Cancer Prev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1007\/s00432-023-04600-w","article-title":"Prevalence and severity of anxiety in cancer patients: results from a multi-center cohort study in Germany","volume":"149","author":"U Goerling","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00345-020-03583-4","article-title":"Should Grade Group 1 (GG1) be called cancer?","volume":"40","author":"CV Labbate","year":"2022","journal-title":"World J Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"388","author":"FC Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-Grade Prostate Cancer: Time to Stop Calling It Cancer","volume":"40","author":"SE Eggener","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MOU.0000000000000945","article-title":"Is Grade Group 1 (Gleason score 3+3=6) adenocarcinoma of the prostate really cancer?","volume":"32","author":"JI Epstein","year":"2022","journal-title":"Curr Opin Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care","volume":"40","author":"JI Epstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.euo.2023.10.005","article-title":"Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population","volume":"7","author":"HV Stroomberg","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"ref9","first-page":"131","article-title":"Microscopic differential diagnosis of latent carcinoma of prostate","volume":"55","author":"RS Totten","year":"1953","journal-title":"AMA Arch Pathol"},{"key":"ref10","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"DF Gleason","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"JI Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","volume":"40","author":"JI Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma","volume":"44","author":"GJLH van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: a prescription for change","volume":"15","author":"LJ Esserman","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ucl.2014.01.006","article-title":"When is prostate cancer really cancer?","volume":"41","author":"DM Berman","year":"2014","journal-title":"Urol Clin North Am"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-Grade Prostate Cancer: Time to Stop Calling It Cancer","volume":"40","author":"SE Eggener","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1464-410X.2004.04848.x","article-title":"Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome","volume":"93","author":"PA Campbell","year":"2004","journal-title":"BJU Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0022-5347(06)00267-9","article-title":"Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts","volume":"175","author":"TD Jones","year":"2006","journal-title":"J Urol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2019.10.002","article-title":"Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?","volume":"38","author":"AE Hentschel","year":"2020","journal-title":"Urol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors","volume":"2","author":"YE Nikiforov","year":"2016","journal-title":"JAMA Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00268-017-4182-5","article-title":"Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?","volume":"42","author":"DN Parente","year":"2018","journal-title":"World J Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care","volume":"40","author":"JI Epstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2025.02.029","article-title":"Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach","volume":"88","author":"RB Shah","year":"2025","journal-title":"Eur Urol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+3.0.co;2-l","article-title":"Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer","volume":"71","author":"TA Stamey","year":"1993","journal-title":"Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"JI Epstein","year":"1994","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"HM Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bju.12879","article-title":"Disease-specific death and metastasis do not occur in patients with Gleason score \u22646 at radical prostatectomy","volume":"116","author":"CF Kweldam","year":"2015","journal-title":"BJU Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0090-4295(99)80441-5","article-title":"Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions","volume":"47","author":"DF Gleason","year":"1996","journal-title":"Urology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.urolonc.2024.05.012","article-title":"A contemporary review: mpMRI in prostate cancer screening and diagnosis","volume":"43","author":"BM Launer","year":"2025","journal-title":"Urol Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis","volume":"382","author":"M Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.eururo.2019.09.005","article-title":"The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy","volume":"77","author":"G Gandaglia","year":"2020","journal-title":"Eur Urol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/sim.6003","article-title":"Modeling grade progression in an active surveillance study","volume":"33","author":"LYT Inoue","year":"2014","journal-title":"Stat Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/hupa.2001.21135","article-title":"Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist","volume":"32","author":"WC Allsbrook","year":"2001","journal-title":"Hum Pathol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/hupa.2001.2113411172298","article-title":"Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists","volume":"32","author":"WC Allsbrook","year":"2001","journal-title":"Hum Pathol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/his.12976","article-title":"Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists","volume":"69","author":"CF Kweldam","year":"2016","journal-title":"Histopathology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.euo.2023.10.005","article-title":"Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population","volume":"7","author":"HV Stroomberg","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"MC Haffner","year":"2013","journal-title":"J Clin Invest"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"SC Baca","year":"2013","journal-title":"Cell"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1158\/1078-0432.CCR-08-2927","article-title":"Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States","volume":"15","author":"J-M Mosquera","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/modpathol.2016.63","article-title":"PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance","volume":"29","author":"BJ Trock","year":"2016","journal-title":"Mod Pathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123468","article-title":"Transcriptomic heterogeneity in multifocal prostate cancer","volume":"3","author":"SS Salami","year":"2018","journal-title":"JCI Insight"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.juro.2016.08.091","article-title":"Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential","volume":"197","author":"EA Klein","year":"2017","journal-title":"J Urol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1097\/01.ju.0000169134.28610.66","article-title":"Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens","volume":"174","author":"L Cheng","year":"2005","journal-title":"J Urol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/PAP.0000000000000192","article-title":"Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management","volume":"25","author":"JK Nguyen","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/his.15231","article-title":"Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage","volume":"85","author":"JK Nguyen","year":"2024","journal-title":"Histopathology"},{"key":"ref46","first-page":"4792","article-title":"Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer","volume":"9","author":"G Ayala","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"SP Porten","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort","volume":"77","author":"JJ Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling","volume":"82","author":"WG Brisbane","year":"2022","journal-title":"Eur Urol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline","volume":"38","author":"SE Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"P Cornford","year":"2024","journal-title":"Eur Urol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2728-9305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:41:03Z","timestamp":1771285263000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2728-9305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":51,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2728-9305","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}